Kiniksa Pharmaceuticals, Ltd.
Lexington, Massachusetts, United States · Biopharma, Biotechnology, Healthcare
Kiniksa Pharmaceuticals is developing therapies for inflammatory and autoimmune conditions.
Key facts
- Headquarters
- Lexington, Massachusetts, United States
- Employees
- 428
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (KNSA)
- Website
- www.kiniksa.com
- Company page
Recent activity at Kiniksa Pharmaceuticals, Ltd.
- : Kiniksa Pharmaceuticals Appoints Ross Moat as President and COO
- : SEC 8-K (5.02):
- : SEC 8-K (1.01):
- : SEC 8-K (5.02): On April 30, 2026, Eben Tessari resigned as Chief Strategy Officer of Kiniksa Pharmaceuticals International, plc to pursue another executive opportunity within the life sciences industry. His resignation will take effect on May 15, 2026, after which he will transition to a consulting role under a Consulting Agreement that commences the same day. Mr. Tessari will provide strategic and operational services and will act as a special advisor to the Science and Research Committee, earning $450 per hour for up to 20 hours a month, along with reimbursement of travel expenses. His resignation was not due to any disagreement with the Company.
- : SEC 8-K (5.02):
- : SEC 8-K (2.02): On January 12, 2026, Kiniksa Pharmaceuticals International, plc issued a press release detailing its financial performance for the year 2025, highlighting that ARCALYST net product revenue reached $677.5 million (unaudited). The gross-to-net metric was reported at 8.4% for the same period, indicating the company’s pricing strategy and market conditions. As of December 31, 2025, Kiniksa reported having $414.1 million in cash, cash equivalents, and short-term investments, while maintaining a debt-free status. This financial health positions the company favorably for future investments and operations.
- : Kiniksa Pharmaceuticals Partners with Carly Pearce to Expand Life DisRPted™ Campaign for Recurrent Pericarditis Awareness
- : Kiniksa Pharmaceuticals, Ltd.
- : Kiniksa Pharmaceuticals, Ltd.
- : Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd. funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2019 | Venture | $5.9M |
Leadership
- Nisha, Senior Director Regulatory Affairs (CMC)
- SANJ PATEL, Executive Officer, Director
- FELIX BAKER, Director
- STEPHEN BIGGAR, Director
- RICHARD LEVY, Director
- THOMAS MALLEY, Director
- TRACEY MCCAIN, Director
- KIMBERLY POPOVITS, Director
- BARRY QUART, Director
- G. COLE, Director
Verified email and direct lines for Kiniksa Pharmaceuticals, Ltd.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Kiniksa Pharmaceuticals, Ltd. files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Kiniksa Pharmaceuticals, Ltd. in the news
- Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance (Jun 16, 2026)
- We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance (May 08, 2026)
- KNSA Stock Price and Chart — NASDAQ:KNSA - TradingView (May 23, 2018)
- Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution - Yahoo Finance (Jul 28, 2026)
- KNSA News Today | Why did Kiniksa Pharmaceuticals International stock go up today? - MarketBeat (Jun 22, 2018)
- Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution - Yahoo Finance (Oct 27, 2026)
- Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026 - Yahoo Finance UK (Oct 22, 2026)
- Kiniksa Pharmaceuticals, Ltd. (KNSA) stock price, news, quote and history - Yahoo Finance UK (Jun 23, 2020)
Companies similar to Kiniksa Pharmaceuticals, Ltd.
- Crinetics Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- Madrigal Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- Syndax Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- Parabilis Medicines · Biopharma, Biotechnology, Healthcare, Pharmaceutical
- Aquestive Therapeutics, Inc. · Biopharma, Biotechnology, Healthcare, Pharmaceutical
About Kiniksa Pharmaceuticals, Ltd.: questions and answers
What does Kiniksa Pharmaceuticals, Ltd. do?
Kiniksa Pharmaceuticals is developing therapies for inflammatory and autoimmune conditions.
Where is Kiniksa Pharmaceuticals, Ltd. headquartered?
Kiniksa Pharmaceuticals, Ltd. is headquartered in Lexington, Massachusetts, United States.
How many employees does Kiniksa Pharmaceuticals, Ltd. have?
Kiniksa Pharmaceuticals, Ltd. has about 428 employees.
Has Kiniksa Pharmaceuticals, Ltd. raised funding?
Yes. Fundz has recorded 1 funding event for Kiniksa Pharmaceuticals, Ltd.. The most recent, $5.9M, was in Apr 2019.
What is the latest news on Kiniksa Pharmaceuticals, Ltd.?
On Oct 22, 2026, Kiniksa Pharmaceuticals Appoints Ross Moat as President and COO
Is Kiniksa Pharmaceuticals, Ltd. a public company?
Yes. Kiniksa Pharmaceuticals, Ltd. is publicly traded under the ticker KNSA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy